Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MedLeanRx vs No BS RX

By GLP-1 ScorecardUpdated

MedLeanRxFactor scores not reassessed.
Site position #73

Lower score

No BS RXFactor scores not reassessed.
Site position #23

Higher score

Score comparison

No BS RX has the higher recorded score — 82.8/100 to 73.9/100.

No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.

Before you choose

Before comparing the headline prices, the MedLeanRx review and the No BS RX review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, MedLeanRx vs PCOS Sisters and Mevo Health vs No BS RX compare each of them with another graded program, and the list of alternatives to MedLeanRx ranks the programs closest to MedLeanRx on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the Peter MD review covers one graded close to these two, at 78.1/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueNo BS RX +18
74
92
Dose & formulationMedLeanRx +3
93
90
Clinical oversightMedLeanRx +5
77
72
Labs & monitoringNo BS RX +16
52
68
FulfillmentNo BS RX +17
77
94
Contract termsNo BS RX +19
55
74
MedLeanRx · top barNo BS RX · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricMedLeanRxNo BS RX
WeighScore73.9/10082.8/100
GradeCB−
Site position#73#23
SemaglutideFrom $149/mo advertised for compounded semaglutide; confirm selected quote$149/mo advertised for standard compounded injection; low-dose priced separately
Tirzepatide$269 listed on the injection card; confirm charge and term$225/mo advertised for standard compounded injection; low-dose priced separately
CoverageTexas programConfirm program availability for your state
Brand-name accessYesYes
Oral / sublingualYesYes
MedLeanRx

Site position #73 · C

Factor scores not reassessed.

Strengths

  • Separates semaglutide vial and tablet listings
  • Identifies the medication as a separate charge on the Wegovy pill card

What to consider

  • Starting prices depend on the prescribed product and dose
  • The terms exclude refunds for listed fees and services already rendered
  • Confirm the next charge and the dispensing pharmacy before paying
No BS RX

Site position #23 · B−

Factor scores not reassessed.

Strengths

  • Displays monthly and prepaid amounts by program
  • Advertises consultation, medication, shipping and messaging in the compounded plans
  • Lists branded Ozempic and Zepbound separately

What to consider

  • The $115 headline applies to low-dose programs
  • Plans renew automatically at the then-current rate
  • Cancellation generally stops future billing without refunding the current period

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard